Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 8, 2026 · Investor press release · Financial statements
Neurogene Inc.
42
Investor press release
Jun 8, 2026
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
Neurogene Inc. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim P…
The filing reports Items 7.01, 9.01. None of these codes are typically workforce-tagged, but analysts still review them for indirect labor-market signals.
Neurogene Inc. filed this 8-K with the SEC. cutoffs links it to the employer's layoff history, visa filings, and other labor-market signals.
